Procter & Gamble will acquire supplements brand Thorne for $3.8 billion, CEO tells CNBC
P&G CEO Shailesh Jejurikar said the acquisition is a play to grow the company's health business on CNBC's "Squawk on the Street."
Procter & Gamble is set to acquire health supplement brand Thorne for a price tag of $3.8 billion, according to CEO Shailesh Jejurikar's remarks on CNBC's Squawk on the Street. The acquisition aims to bolster P&G's health and wellness division, which already includes other supplement brands like Metamucil, Align Probiotic, and New Chapter vitamins.
Jejurikar expressed satisfaction with Thorne, stating it is "a really well-run operation, and it's been around for a long time." Founded in 1984 and going public in late 2021, Thorne was later taken private in 2023 by L Catterton for $680 million. In 2025, Thorne's annual revenue exceeded $500 million, indicating a growing interest in the supplement market, particularly among younger consumers.
Thorne's CEO, Colin Watts, had previously predicted the brand's potential to reach billion-dollar status within a few years. The acquisition is part of a trend where consumer giants are investing in upstart health and wellness brands, as seen with Unilever's recent purchase of Grüns, a gummy supplement brand.
Written by urgent.news from CNBC World's reporting — not their text. Machine-written — may contain errors; check the original before relying on it.
This story
This is one outlet's version. Read the fullest account.
